CoolSculpting works by taking advantage of the fact that fat cells are more sensitive to cold than the other cells around them. This basic scientific fact was first discovered in 1970 by doctors observing children who sucked on popsicles for hours, and ended up having first soreness, and later dimples, caused by loss of fat cells! Fast forward about 20 years, and Harvard scientists revisited this fact, and realized that they could turn this science into a system for aesthetic sculpting of fatty bulges. The key was to find the ‘sweet spot’ of time and temperature, which would kill some fat cells but not damage surrounding structures such as skin. They called the public company that makes the systems Zeltiq. The proof of the success of this concept and treatment: Zeltiq was bought out by Allergan in 2016 for whopping 2.5 billion! This was the largest sale of a single medical device company in history.
1 July 2015: The CMA is considering whether it is or may be the case that this transaction has resulted in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation has resulted, or may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.